Good morning :)
Place Order
Add to Watchlist

Lyka Labs Ltd

LYKALABS Share Price

117.550.53% (-0.63)
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health Care
Pharmaceuticals
Smallcap

With a market cap of ₹421 cr, stock is ranked 1,921

High Risk

Stock is 3.35x as volatile as Nifty

LYKALABS Stock Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

Avg

Average profitability - not good, not bad

Entry point

Avg

The stock is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health Care
Pharmaceuticals
Smallcap

With a market cap of ₹421 cr, stock is ranked 1,921

High Risk

Stock is 3.35x as volatile as Nifty

LYKALABS Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
53.196.08—
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
35.346.490.86%

LYKALABS Analyst Ratings & Forecast

—
Analyst Ratings data is currently unavailable for this stock

Price Upside

Earnings Growth

Rev. Growth

LYKALABS Company Profile

Lyka Labs Limited is a pharmaceutical products and services provider. The Company is primarily engaged in formulation and manufacturing lyophilized products.

LYKALABS Similar Stocks (Peers)

Compare with peers 
Sun Pharmaceutical Industries Ltd
SUNPHARMA
PE Ratio
36.61
1Y Return
14.76%
Buy Reco %
87.88
Cipla Ltd
CIPLA
PE Ratio
22.57
1Y Return
1.44%
Buy Reco %
74.19
Torrent Pharmaceuticals Ltd
TORNTPHARM
PE Ratio
55.52
1Y Return
17.07%
Buy Reco %
72.00
Dr Reddy's Laboratories Ltd
DRREDDY
PE Ratio
18.37
1Y Return
7.92%
Buy Reco %
53.33
Mankind Pharma Ltd
MANKIND
PE Ratio
48.76
1Y Return
13.59%
Buy Reco %
81.25
Compare with Peers

LYKALABS Forecasts

LYKALABS Forecast

empty forecast

Forecast data is currently unavailable

Forecast data is currently unavailable

Price

Price Upside

Revenue

Revenue Growth

Earnings

Earnings Per Share

LYKALABS

Income

Balance Sheet

Cash Flow

LYKALABS Income Statement

Industry refers to the sub-sector this company belongs to.
Higher than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 9.1%, vs industry avg of 9.02%

Constant Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share stayed at 0.03%

Loading...

Financial YearFY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Total Revenue112.3265.3972.8766.3387.81196.1796.72112.64140.73140.72
Raw Materialssubtract55.7827.5835.8036.4634.9153.3838.7645.64120.56120.56
Power & Fuel Costsubtract1.901.862.282.562.943.923.603.93
Employee Costsubtract17.2416.9814.6913.8614.5718.0618.6126.77
Selling & Administrative Expensessubtract6.338.7611.309.007.5713.9212.7116.05
Operating & Other expensessubtract10.209.399.7538.247.7110.1710.193.50
Depreciation/Amortizationsubtract10.2511.287.318.018.3217.3514.1512.806.776.77
Interest & Other Itemssubtract18.729.587.1720.0725.9420.1311.874.892.272.27
Taxes & Other Itemssubtract-2.57-2.77-9.87-1.33-2.6020.240.041.563.203.19
EPS-2.51-6.88-1.98-21.31-4.0313.59-4.45-0.782.222.40
DPS0.000.000.000.000.000.000.000.000.000.00
Payout ratio0.000.000.000.000.000.000.000.000.000.00
See Costs

EPS and DPS in ₹. Other numbers except Payout Ratio in ₹ cr

LYKALABS Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2014

Annual report

PDF
FY 2015

Annual report

PDF
FY 2016

Annual report

PDF
FY 2017

Annual report

PDF
FY 2018

Annual report

PDF
FY 2019

Annual report

PDF
FY 2020

Annual report

PDF
FY 2021

Annual report

PDF
FY 2022

Annual report

PDF
FY 2023

Annual report

PDF
 

LYKALABS Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Valuation

Technical

Forecast

ScreenerCompare valuation on Screener

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Lyka Labs Ltd53.196.08—
Sun Pharmaceutical Industries Ltd36.615.960.96%
Cipla Ltd22.574.441.09%
Torrent Pharmaceuticals Ltd55.5215.481.02%

LYKALABS Stock Price Comparison

Compare LYKALABS with any stock or ETF
Compare LYKALABS with any stock or ETF
LYKALABS
Loading...

LYKALABS Shareholdings

LYKALABS Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

LYKALABS Institutional Holdings Trend

Decreased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has decreased by 1.31%

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

LYKALABS Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding58.16%0.01%0.66%0.23%40.94%

Jun 2024

Sep 2024

Dec 2024

Mar 2025

LYKALABS Shareholding History

MarAprJunSepDec '24Mar0.17%0.16%0.15%0.15%0.15%0.23%

LYKALABS Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing LYKALABS stock

Looks like this stock is not in any smallcase yet.

LYKALABS Events

LYKALABS Dividend Trend

No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year

LYKALABS has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

LYKALABS Dividends

Hmm, looks like data is unavailable here. Please come back after some time

LYKALABS Stock News & Opinions

Earnings
Lyka Labs reports consolidated net profit of Rs 2.03 crore in the March 2025 quarter

Net profit of Lyka Labs reported to Rs 2.03 crore in the quarter ended March 2025 as against net loss of Rs 2.09 crore during the previous quarter ended March 2024. Sales rose 20.38% to Rs 33.43 crore in the quarter ended March 2025 as against Rs 27.77 crore during the previous quarter ended March 2024. For the full year,net profit reported to Rs 7.93 crore in the year ended March 2025 as against net loss of Rs 2.62 crore during the previous year ended March 2024. Sales rose 24.56% to Rs 138.50 crore in the year ended March 2025 as against Rs 111.19 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales33.4327.77 20 138.50111.19 25 OPM %12.207.27 -12.9514.14 - PBDT4.431.25 254 17.8912.28 46 PBT3.02-1.65 LP 11.12-0.52 LP NP2.03-2.09 LP 7.93-2.62 LP Powered by Capital Market - Live

1 week agoCapital Market - Live
Corporate
Lyka Labs to discuss results

Lyka Labs will hold a meeting of the Board of Directors of the Company on 26 May 2025.Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Earnings
Lyka Labs consolidated net profit rises 52.25% in the December 2024 quarter

Net profit of Lyka Labs rose 52.25% to Rs 2.71 crore in the quarter ended December 2024 as against Rs 1.78 crore during the previous quarter ended December 2023. Sales rose 3.81% to Rs 33.80 crore in the quarter ended December 2024 as against Rs 32.56 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales33.8032.56 4 OPM %15.3621.10 - PBDT5.416.13 -12 PBT3.573.29 9 NP2.711.78 52 Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Lyka Labs EGM scheduled

Lyka Labs announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 4 March 2025.Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Lyka Labs announces board meeting date

Lyka Labs will hold a meeting of the Board of Directors of the Company on 4 February 2025.Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Lyka Labs to declare Quarterly Result

Lyka Labs will hold a meeting of the Board of Directors of the Company on 4 February 2025.Powered by Capital Market - Live

5 months agoCapital Market - Live
Earnings
Lyka Labs reports consolidated net profit of Rs 2.10 crore in the September 2024 quarter

Net profit of Lyka Labs reported to Rs 2.10 crore in the quarter ended September 2024 as against net loss of Rs 0.49 crore during the previous quarter ended September 2023. Sales rose 47.05% to Rs 41.16 crore in the quarter ended September 2024 as against Rs 27.99 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales41.1627.99 47 OPM %12.0314.90 - PBDT4.443.23 37 PBT2.67-0.36 LP NP2.10-0.49 LP Powered by Capital Market - Live

6 months agoCapital Market - Live
Corporate
Lyka Labs announces board meeting date

Lyka Labs will hold a meeting of the Board of Directors of the Company on 12 November 2024.Powered by Capital Market - Live

7 months agoCapital Market - Live
Corporate
Lyka Labs to hold board meeting

Lyka Labs will hold a meeting of the Board of Directors of the Company on 11 October 2024Powered by Capital Market - Live

7 months agoCapital Market - Live
Earnings
Lyka Labs reports consolidated net profit of Rs 1.44 crore in the June 2024 quarter

Net profit of Lyka Labs reported to Rs 1.44 crore in the quarter ended June 2024 as against net loss of Rs 1.85 crore during the previous quarter ended June 2023. Sales rose 31.60% to Rs 30.11 crore in the quarter ended June 2024 as against Rs 22.88 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales30.1122.88 32 OPM %12.3211.54 - PBDT3.621.67 117 PBT1.86-1.80 LP NP1.44-1.85 LP Powered by Capital Market - Live

9 months agoCapital Market - Live

Frequently asked questions

  1. What is the share price of Lyka Labs Ltd (LYKALABS) today?

    The share price of LYKALABS as on 4th June 2025 is ₹117.55. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Lyka Labs Ltd (LYKALABS) share?

    The past returns of Lyka Labs Ltd (LYKALABS) share are
    • Past 1 week: 0.68%
    • Past 1 month: 8.45%
    • Past 3 months: 16.53%
    • Past 6 months: -27.92%
    • Past 1 year: 10.81%
    • Past 3 years: 1.36%
    • Past 5 years: 634.04%

  3. What are the peers or stocks similar to Lyka Labs Ltd (LYKALABS)?

    The peers or stocks similar to Lyka Labs Ltd (LYKALABS) include:

  4. What is the market cap of Lyka Labs Ltd (LYKALABS) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Lyka Labs Ltd (LYKALABS) is ₹421.78 Cr as of 4th June 2025.

  5. What is the 52 week high and low of Lyka Labs Ltd (LYKALABS) share?

    The 52-week high of Lyka Labs Ltd (LYKALABS) is ₹176.59 and the 52-week low is ₹96.80.

  6. What is the PE and PB ratio of Lyka Labs Ltd (LYKALABS) stock?

    The P/E (price-to-earnings) ratio of Lyka Labs Ltd (LYKALABS) is 53.19. The P/B (price-to-book) ratio is 6.08.

  7. Which sector does Lyka Labs Ltd (LYKALABS) belong to?

    Lyka Labs Ltd (LYKALABS) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  8. How to buy Lyka Labs Ltd (LYKALABS) shares?

    You can directly buy Lyka Labs Ltd (LYKALABS) shares on Tickertape. Simply sign up, connect your demat account and place your order.